DNMT3A and cancer: Recently, it was shown that in genetically modified human cancer cells including dnmt3a- and -b-deficient cells, dnmt1 is the major de novo methyltransferase for three different CpG island substrates, suggesting that dnmt1 might be considered to possess more diverse and wide-ranging catalytic activities than previously suspected for a simple maintenance enzyme [31].